nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—RET—thyroid cancer	0.316	1	CbGaD
Ponatinib—TEK—Vandetanib—thyroid cancer	0.05	0.103	CbGbCtD
Ponatinib—FLT3—Vandetanib—thyroid cancer	0.0432	0.0887	CbGbCtD
Ponatinib—RET—Vandetanib—thyroid cancer	0.0432	0.0887	CbGbCtD
Ponatinib—KDR—Vandetanib—thyroid cancer	0.0432	0.0887	CbGbCtD
Ponatinib—LYN—Vandetanib—thyroid cancer	0.0382	0.0784	CbGbCtD
Ponatinib—SRC—Vandetanib—thyroid cancer	0.0382	0.0784	CbGbCtD
Ponatinib—LCK—Vandetanib—thyroid cancer	0.0312	0.0641	CbGbCtD
Ponatinib—FGFR1—Sorafenib—thyroid cancer	0.0301	0.0618	CbGbCtD
Ponatinib—RET—Sorafenib—thyroid cancer	0.026	0.0535	CbGbCtD
Ponatinib—FLT3—Sorafenib—thyroid cancer	0.026	0.0535	CbGbCtD
Ponatinib—KDR—Sorafenib—thyroid cancer	0.026	0.0535	CbGbCtD
Ponatinib—ABL1—Vandetanib—thyroid cancer	0.0248	0.0509	CbGbCtD
Ponatinib—KIT—Sorafenib—thyroid cancer	0.0207	0.0425	CbGbCtD
Ponatinib—PDGFRA—Sorafenib—thyroid cancer	0.0207	0.0425	CbGbCtD
Ponatinib—ABCG2—Vandetanib—thyroid cancer	0.00567	0.0116	CbGbCtD
Ponatinib—ABCB11—Doxorubicin—thyroid cancer	0.00436	0.00895	CbGbCtD
Ponatinib—RET—parathyroid gland—thyroid cancer	0.00344	0.119	CbGeAlD
Ponatinib—ABCG2—Sorafenib—thyroid cancer	0.00342	0.00701	CbGbCtD
Ponatinib—ABCG2—Doxorubicin—thyroid cancer	0.00207	0.00425	CbGbCtD
Ponatinib—CYP3A5—Sorafenib—thyroid cancer	0.00189	0.00388	CbGbCtD
Ponatinib—CYP2C8—Sorafenib—thyroid cancer	0.00182	0.00374	CbGbCtD
Ponatinib—Nilotinib—BRAF—thyroid cancer	0.00143	1	CrCbGaD
Ponatinib—ABCB1—Sorafenib—thyroid cancer	0.00123	0.00253	CbGbCtD
Ponatinib—CYP3A4—Vandetanib—thyroid cancer	0.00122	0.00251	CbGbCtD
Ponatinib—CYP2D6—Sorafenib—thyroid cancer	0.00116	0.00238	CbGbCtD
Ponatinib—RET—neck—thyroid cancer	0.00104	0.0362	CbGeAlD
Ponatinib—BCR—saliva-secreting gland—thyroid cancer	0.00102	0.0354	CbGeAlD
Ponatinib—FGFR2—neck—thyroid cancer	0.000992	0.0344	CbGeAlD
Ponatinib—FGFR4—head—thyroid cancer	0.000938	0.0325	CbGeAlD
Ponatinib—BCR—trachea—thyroid cancer	0.000789	0.0273	CbGeAlD
Ponatinib—KDR—neck—thyroid cancer	0.000777	0.0269	CbGeAlD
Ponatinib—FGFR2—saliva-secreting gland—thyroid cancer	0.000774	0.0268	CbGeAlD
Ponatinib—ABCB1—Doxorubicin—thyroid cancer	0.000747	0.00153	CbGbCtD
Ponatinib—CYP3A4—Sorafenib—thyroid cancer	0.000738	0.00151	CbGbCtD
Ponatinib—CYP2D6—Doxorubicin—thyroid cancer	0.000704	0.00145	CbGbCtD
Ponatinib—KIT—neck—thyroid cancer	0.000689	0.0239	CbGeAlD
Ponatinib—FGFR4—lymph node—thyroid cancer	0.000657	0.0227	CbGeAlD
Ponatinib—LYN—head—thyroid cancer	0.000643	0.0223	CbGeAlD
Ponatinib—FGFR3—head—thyroid cancer	0.00064	0.0222	CbGeAlD
Ponatinib—LCK—trachea—thyroid cancer	0.000628	0.0218	CbGeAlD
Ponatinib—BCR—thyroid gland—thyroid cancer	0.000624	0.0216	CbGeAlD
Ponatinib—KDR—saliva-secreting gland—thyroid cancer	0.000606	0.021	CbGeAlD
Ponatinib—FGFR1—thyroid gland—thyroid cancer	0.000555	0.0192	CbGeAlD
Ponatinib—BCR—head—thyroid cancer	0.000554	0.0192	CbGeAlD
Ponatinib—KIT—saliva-secreting gland—thyroid cancer	0.000537	0.0186	CbGeAlD
Ponatinib—PDGFRA—trachea—thyroid cancer	0.000518	0.018	CbGeAlD
Ponatinib—LCK—thyroid gland—thyroid cancer	0.000497	0.0172	CbGeAlD
Ponatinib—RET—thyroid gland—thyroid cancer	0.000497	0.0172	CbGeAlD
Ponatinib—FGFR2—thyroid gland—thyroid cancer	0.000472	0.0164	CbGeAlD
Ponatinib—ABL1—saliva-secreting gland—thyroid cancer	0.000468	0.0162	CbGeAlD
Ponatinib—KDR—trachea—thyroid cancer	0.000468	0.0162	CbGeAlD
Ponatinib—TEK—thyroid gland—thyroid cancer	0.000453	0.0157	CbGeAlD
Ponatinib—CYP3A4—Doxorubicin—thyroid cancer	0.000448	0.000919	CbGbCtD
Ponatinib—RET—head—thyroid cancer	0.000441	0.0153	CbGeAlD
Ponatinib—FGFR2—head—thyroid cancer	0.000419	0.0145	CbGeAlD
Ponatinib—KIT—trachea—thyroid cancer	0.000414	0.0144	CbGeAlD
Ponatinib—PDGFRA—thyroid gland—thyroid cancer	0.00041	0.0142	CbGeAlD
Ponatinib—SRC—thyroid gland—thyroid cancer	0.000402	0.0139	CbGeAlD
Ponatinib—TEK—head—thyroid cancer	0.000402	0.0139	CbGeAlD
Ponatinib—BCR—lymph node—thyroid cancer	0.000388	0.0134	CbGeAlD
Ponatinib—FLT3—lymph node—thyroid cancer	0.000385	0.0133	CbGeAlD
Ponatinib—KDR—thyroid gland—thyroid cancer	0.00037	0.0128	CbGeAlD
Ponatinib—PDGFRA—head—thyroid cancer	0.000364	0.0126	CbGeAlD
Ponatinib—ABL1—trachea—thyroid cancer	0.000361	0.0125	CbGeAlD
Ponatinib—SRC—head—thyroid cancer	0.000357	0.0124	CbGeAlD
Ponatinib—FGFR1—lymph node—thyroid cancer	0.000345	0.0119	CbGeAlD
Ponatinib—KDR—head—thyroid cancer	0.000328	0.0114	CbGeAlD
Ponatinib—KIT—thyroid gland—thyroid cancer	0.000328	0.0114	CbGeAlD
Ponatinib—RET—lymph node—thyroid cancer	0.000309	0.0107	CbGeAlD
Ponatinib—LCK—lymph node—thyroid cancer	0.000309	0.0107	CbGeAlD
Ponatinib—ABCG2—saliva-secreting gland—thyroid cancer	0.000295	0.0102	CbGeAlD
Ponatinib—KIT—head—thyroid cancer	0.000291	0.0101	CbGeAlD
Ponatinib—ABL1—thyroid gland—thyroid cancer	0.000285	0.00988	CbGeAlD
Ponatinib—TEK—lymph node—thyroid cancer	0.000281	0.00974	CbGeAlD
Ponatinib—ABL1—Daunorubicin—Epirubicin—thyroid cancer	0.000262	0.173	CbGdCrCtD
Ponatinib—ABL1—Idarubicin—Epirubicin—thyroid cancer	0.000262	0.173	CbGdCrCtD
Ponatinib—ABL1—Doxorubicin—Epirubicin—thyroid cancer	0.000262	0.173	CbGdCrCtD
Ponatinib—PDGFRA—lymph node—thyroid cancer	0.000255	0.00882	CbGeAlD
Ponatinib—ABL1—head—thyroid cancer	0.000253	0.00877	CbGeAlD
Ponatinib—SRC—lymph node—thyroid cancer	0.00025	0.00865	CbGeAlD
Ponatinib—ABL1—Epirubicin—Doxorubicin—thyroid cancer	0.000242	0.16	CbGdCrCtD
Ponatinib—ABL1—Idarubicin—Doxorubicin—thyroid cancer	0.000242	0.16	CbGdCrCtD
Ponatinib—ABL1—Daunorubicin—Doxorubicin—thyroid cancer	0.000242	0.16	CbGdCrCtD
Ponatinib—KDR—lymph node—thyroid cancer	0.00023	0.00796	CbGeAlD
Ponatinib—KIT—lymph node—thyroid cancer	0.000204	0.00705	CbGeAlD
Ponatinib—ABCG2—thyroid gland—thyroid cancer	0.00018	0.00623	CbGeAlD
Ponatinib—ABL1—lymph node—thyroid cancer	0.000177	0.00614	CbGeAlD
Ponatinib—ABCB1—trachea—thyroid cancer	0.000112	0.00389	CbGeAlD
Ponatinib—ABCG2—lymph node—thyroid cancer	0.000112	0.00387	CbGeAlD
Ponatinib—CYP2D6—head—thyroid cancer	0.000109	0.00379	CbGeAlD
Ponatinib—Neck pain—Epirubicin—thyroid cancer	0.0001	0.00115	CcSEcCtD
Ponatinib—Hypocalcaemia—Doxorubicin—thyroid cancer	9.98e-05	0.00115	CcSEcCtD
Ponatinib—Arthralgia—Sorafenib—thyroid cancer	9.95e-05	0.00115	CcSEcCtD
Ponatinib—Myalgia—Sorafenib—thyroid cancer	9.95e-05	0.00115	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	9.88e-05	0.00114	CcSEcCtD
Ponatinib—Pulmonary embolism—Epirubicin—thyroid cancer	9.88e-05	0.00114	CcSEcCtD
Ponatinib—Phosphatase alkaline increased—Epirubicin—thyroid cancer	9.88e-05	0.00114	CcSEcCtD
Ponatinib—Hyperuricaemia—Doxorubicin—thyroid cancer	9.85e-05	0.00114	CcSEcCtD
Ponatinib—Dry mouth—Sorafenib—thyroid cancer	9.73e-05	0.00112	CcSEcCtD
Ponatinib—Diarrhoea—Vandetanib—thyroid cancer	9.67e-05	0.00112	CcSEcCtD
Ponatinib—Blood bilirubin increased—Doxorubicin—thyroid cancer	9.66e-05	0.00112	CcSEcCtD
Ponatinib—Creatinine increased—Doxorubicin—thyroid cancer	9.6e-05	0.00111	CcSEcCtD
Ponatinib—Influenza like illness—Epirubicin—thyroid cancer	9.59e-05	0.00111	CcSEcCtD
Ponatinib—Bone pain—Doxorubicin—thyroid cancer	9.54e-05	0.0011	CcSEcCtD
Ponatinib—Infection—Sorafenib—thyroid cancer	9.47e-05	0.00109	CcSEcCtD
Ponatinib—Skin exfoliation—Epirubicin—thyroid cancer	9.43e-05	0.00109	CcSEcCtD
Ponatinib—Fluid retention—Epirubicin—thyroid cancer	9.38e-05	0.00108	CcSEcCtD
Ponatinib—Nervous system disorder—Sorafenib—thyroid cancer	9.35e-05	0.00108	CcSEcCtD
Ponatinib—Dizziness—Vandetanib—thyroid cancer	9.35e-05	0.00108	CcSEcCtD
Ponatinib—Thrombocytopenia—Sorafenib—thyroid cancer	9.34e-05	0.00108	CcSEcCtD
Ponatinib—Blood uric acid increased—Doxorubicin—thyroid cancer	9.31e-05	0.00107	CcSEcCtD
Ponatinib—Neuropathy—Epirubicin—thyroid cancer	9.27e-05	0.00107	CcSEcCtD
Ponatinib—Skin disorder—Sorafenib—thyroid cancer	9.26e-05	0.00107	CcSEcCtD
Ponatinib—Neck pain—Doxorubicin—thyroid cancer	9.25e-05	0.00107	CcSEcCtD
Ponatinib—Musculoskeletal pain—Doxorubicin—thyroid cancer	9.25e-05	0.00107	CcSEcCtD
Ponatinib—Phosphatase alkaline increased—Doxorubicin—thyroid cancer	9.14e-05	0.00106	CcSEcCtD
Ponatinib—Pulmonary embolism—Doxorubicin—thyroid cancer	9.14e-05	0.00106	CcSEcCtD
Ponatinib—Dry eye—Epirubicin—thyroid cancer	9.12e-05	0.00105	CcSEcCtD
Ponatinib—Vomiting—Vandetanib—thyroid cancer	8.99e-05	0.00104	CcSEcCtD
Ponatinib—Ecchymosis—Epirubicin—thyroid cancer	8.93e-05	0.00103	CcSEcCtD
Ponatinib—Rash—Vandetanib—thyroid cancer	8.91e-05	0.00103	CcSEcCtD
Ponatinib—Dermatitis—Vandetanib—thyroid cancer	8.9e-05	0.00103	CcSEcCtD
Ponatinib—Influenza like illness—Doxorubicin—thyroid cancer	8.88e-05	0.00102	CcSEcCtD
Ponatinib—ABCB1—thyroid gland—thyroid cancer	8.87e-05	0.00307	CbGeAlD
Ponatinib—Headache—Vandetanib—thyroid cancer	8.86e-05	0.00102	CcSEcCtD
Ponatinib—Skin exfoliation—Doxorubicin—thyroid cancer	8.73e-05	0.00101	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Sorafenib—thyroid cancer	8.69e-05	0.001	CcSEcCtD
Ponatinib—Fluid retention—Doxorubicin—thyroid cancer	8.68e-05	0.001	CcSEcCtD
Ponatinib—Neuropathy—Doxorubicin—thyroid cancer	8.58e-05	0.000991	CcSEcCtD
Ponatinib—Sepsis—Epirubicin—thyroid cancer	8.57e-05	0.00099	CcSEcCtD
Ponatinib—Dyspnoea—Sorafenib—thyroid cancer	8.5e-05	0.000981	CcSEcCtD
Ponatinib—Dry eye—Doxorubicin—thyroid cancer	8.44e-05	0.000975	CcSEcCtD
Ponatinib—Nausea—Vandetanib—thyroid cancer	8.4e-05	0.000969	CcSEcCtD
Ponatinib—Dyspepsia—Sorafenib—thyroid cancer	8.39e-05	0.000969	CcSEcCtD
Ponatinib—Decreased appetite—Sorafenib—thyroid cancer	8.29e-05	0.000957	CcSEcCtD
Ponatinib—Ecchymosis—Doxorubicin—thyroid cancer	8.26e-05	0.000954	CcSEcCtD
Ponatinib—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	8.24e-05	0.000952	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Sorafenib—thyroid cancer	8.23e-05	0.00095	CcSEcCtD
Ponatinib—Fatigue—Sorafenib—thyroid cancer	8.22e-05	0.000949	CcSEcCtD
Ponatinib—Constipation—Sorafenib—thyroid cancer	8.15e-05	0.000941	CcSEcCtD
Ponatinib—Pain—Sorafenib—thyroid cancer	8.15e-05	0.000941	CcSEcCtD
Ponatinib—Sepsis—Doxorubicin—thyroid cancer	7.93e-05	0.000916	CcSEcCtD
Ponatinib—Cardiac failure congestive—Epirubicin—thyroid cancer	7.91e-05	0.000913	CcSEcCtD
Ponatinib—ABCB1—head—thyroid cancer	7.87e-05	0.00273	CbGeAlD
Ponatinib—Gastrointestinal pain—Sorafenib—thyroid cancer	7.8e-05	0.0009	CcSEcCtD
Ponatinib—Hot flush—Epirubicin—thyroid cancer	7.66e-05	0.000885	CcSEcCtD
Ponatinib—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	7.63e-05	0.000881	CcSEcCtD
Ponatinib—Menopausal symptoms—Epirubicin—thyroid cancer	7.6e-05	0.000877	CcSEcCtD
Ponatinib—Dermatitis exfoliative—Epirubicin—thyroid cancer	7.6e-05	0.000877	CcSEcCtD
Ponatinib—Abdominal pain—Sorafenib—thyroid cancer	7.54e-05	0.00087	CcSEcCtD
Ponatinib—Body temperature increased—Sorafenib—thyroid cancer	7.54e-05	0.00087	CcSEcCtD
Ponatinib—Cardiac failure—Epirubicin—thyroid cancer	7.35e-05	0.000848	CcSEcCtD
Ponatinib—Lethargy—Epirubicin—thyroid cancer	7.32e-05	0.000845	CcSEcCtD
Ponatinib—Cerebrovascular accident—Epirubicin—thyroid cancer	7.32e-05	0.000845	CcSEcCtD
Ponatinib—Cardiac failure congestive—Doxorubicin—thyroid cancer	7.32e-05	0.000845	CcSEcCtD
Ponatinib—Hyponatraemia—Epirubicin—thyroid cancer	7.2e-05	0.000831	CcSEcCtD
Ponatinib—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	7.17e-05	0.000828	CcSEcCtD
Ponatinib—Pain in extremity—Epirubicin—thyroid cancer	7.17e-05	0.000828	CcSEcCtD
Ponatinib—Hot flush—Doxorubicin—thyroid cancer	7.09e-05	0.000819	CcSEcCtD
Ponatinib—Migraine—Epirubicin—thyroid cancer	7.06e-05	0.000815	CcSEcCtD
Ponatinib—Menopausal symptoms—Doxorubicin—thyroid cancer	7.03e-05	0.000812	CcSEcCtD
Ponatinib—Dermatitis exfoliative—Doxorubicin—thyroid cancer	7.03e-05	0.000812	CcSEcCtD
Ponatinib—Face oedema—Epirubicin—thyroid cancer	6.92e-05	0.000799	CcSEcCtD
Ponatinib—Asthenia—Sorafenib—thyroid cancer	6.84e-05	0.00079	CcSEcCtD
Ponatinib—Cardiac failure—Doxorubicin—thyroid cancer	6.8e-05	0.000785	CcSEcCtD
Ponatinib—Lethargy—Doxorubicin—thyroid cancer	6.77e-05	0.000782	CcSEcCtD
Ponatinib—Cerebrovascular accident—Doxorubicin—thyroid cancer	6.77e-05	0.000782	CcSEcCtD
Ponatinib—Pruritus—Sorafenib—thyroid cancer	6.75e-05	0.000779	CcSEcCtD
Ponatinib—Blood creatinine increased—Epirubicin—thyroid cancer	6.72e-05	0.000775	CcSEcCtD
Ponatinib—Dehydration—Epirubicin—thyroid cancer	6.67e-05	0.00077	CcSEcCtD
Ponatinib—Hyponatraemia—Doxorubicin—thyroid cancer	6.66e-05	0.000769	CcSEcCtD
Ponatinib—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	6.63e-05	0.000766	CcSEcCtD
Ponatinib—Pain in extremity—Doxorubicin—thyroid cancer	6.63e-05	0.000766	CcSEcCtD
Ponatinib—Dry skin—Epirubicin—thyroid cancer	6.57e-05	0.000759	CcSEcCtD
Ponatinib—Migraine—Doxorubicin—thyroid cancer	6.53e-05	0.000754	CcSEcCtD
Ponatinib—Hypokalaemia—Epirubicin—thyroid cancer	6.53e-05	0.000753	CcSEcCtD
Ponatinib—Diarrhoea—Sorafenib—thyroid cancer	6.52e-05	0.000753	CcSEcCtD
Ponatinib—Breast disorder—Epirubicin—thyroid cancer	6.48e-05	0.000748	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	6.46e-05	0.000745	CcSEcCtD
Ponatinib—Nasopharyngitis—Epirubicin—thyroid cancer	6.41e-05	0.00074	CcSEcCtD
Ponatinib—Face oedema—Doxorubicin—thyroid cancer	6.4e-05	0.000739	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Epirubicin—thyroid cancer	6.32e-05	0.00073	CcSEcCtD
Ponatinib—Dizziness—Sorafenib—thyroid cancer	6.31e-05	0.000728	CcSEcCtD
Ponatinib—Abdominal distension—Epirubicin—thyroid cancer	6.24e-05	0.00072	CcSEcCtD
Ponatinib—Blood creatinine increased—Doxorubicin—thyroid cancer	6.22e-05	0.000718	CcSEcCtD
Ponatinib—Dehydration—Doxorubicin—thyroid cancer	6.17e-05	0.000712	CcSEcCtD
Ponatinib—Dry skin—Doxorubicin—thyroid cancer	6.08e-05	0.000702	CcSEcCtD
Ponatinib—Pancreatitis—Epirubicin—thyroid cancer	6.08e-05	0.000701	CcSEcCtD
Ponatinib—Vomiting—Sorafenib—thyroid cancer	6.06e-05	0.0007	CcSEcCtD
Ponatinib—Hypokalaemia—Doxorubicin—thyroid cancer	6.04e-05	0.000697	CcSEcCtD
Ponatinib—Angina pectoris—Epirubicin—thyroid cancer	6.04e-05	0.000697	CcSEcCtD
Ponatinib—Rash—Sorafenib—thyroid cancer	6.01e-05	0.000694	CcSEcCtD
Ponatinib—Dermatitis—Sorafenib—thyroid cancer	6.01e-05	0.000693	CcSEcCtD
Ponatinib—Breast disorder—Doxorubicin—thyroid cancer	6e-05	0.000692	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	5.97e-05	0.00069	CcSEcCtD
Ponatinib—Headache—Sorafenib—thyroid cancer	5.97e-05	0.00069	CcSEcCtD
Ponatinib—Nasopharyngitis—Doxorubicin—thyroid cancer	5.93e-05	0.000685	CcSEcCtD
Ponatinib—Pancytopenia—Epirubicin—thyroid cancer	5.89e-05	0.000679	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	5.85e-05	0.000676	CcSEcCtD
Ponatinib—Neutropenia—Epirubicin—thyroid cancer	5.79e-05	0.000669	CcSEcCtD
Ponatinib—Abdominal distension—Doxorubicin—thyroid cancer	5.77e-05	0.000666	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Epirubicin—thyroid cancer	5.76e-05	0.000665	CcSEcCtD
Ponatinib—Nausea—Sorafenib—thyroid cancer	5.66e-05	0.000654	CcSEcCtD
Ponatinib—Pancreatitis—Doxorubicin—thyroid cancer	5.62e-05	0.000649	CcSEcCtD
Ponatinib—Weight decreased—Epirubicin—thyroid cancer	5.61e-05	0.000647	CcSEcCtD
Ponatinib—Hyperglycaemia—Epirubicin—thyroid cancer	5.59e-05	0.000645	CcSEcCtD
Ponatinib—Angina pectoris—Doxorubicin—thyroid cancer	5.59e-05	0.000645	CcSEcCtD
Ponatinib—Pneumonia—Epirubicin—thyroid cancer	5.56e-05	0.000642	CcSEcCtD
Ponatinib—Infestation NOS—Epirubicin—thyroid cancer	5.53e-05	0.000638	CcSEcCtD
Ponatinib—Infestation—Epirubicin—thyroid cancer	5.53e-05	0.000638	CcSEcCtD
Ponatinib—ABCB1—lymph node—thyroid cancer	5.51e-05	0.00191	CbGeAlD
Ponatinib—Pancytopenia—Doxorubicin—thyroid cancer	5.45e-05	0.000629	CcSEcCtD
Ponatinib—Neuropathy peripheral—Epirubicin—thyroid cancer	5.42e-05	0.000625	CcSEcCtD
Ponatinib—Stomatitis—Epirubicin—thyroid cancer	5.39e-05	0.000622	CcSEcCtD
Ponatinib—Jaundice—Epirubicin—thyroid cancer	5.39e-05	0.000622	CcSEcCtD
Ponatinib—Urinary tract infection—Epirubicin—thyroid cancer	5.37e-05	0.00062	CcSEcCtD
Ponatinib—Neutropenia—Doxorubicin—thyroid cancer	5.36e-05	0.000619	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Doxorubicin—thyroid cancer	5.33e-05	0.000615	CcSEcCtD
Ponatinib—Hepatobiliary disease—Epirubicin—thyroid cancer	5.23e-05	0.000603	CcSEcCtD
Ponatinib—Epistaxis—Epirubicin—thyroid cancer	5.21e-05	0.000602	CcSEcCtD
Ponatinib—Weight decreased—Doxorubicin—thyroid cancer	5.19e-05	0.000599	CcSEcCtD
Ponatinib—Hyperglycaemia—Doxorubicin—thyroid cancer	5.17e-05	0.000597	CcSEcCtD
Ponatinib—Pneumonia—Doxorubicin—thyroid cancer	5.14e-05	0.000594	CcSEcCtD
Ponatinib—Infestation NOS—Doxorubicin—thyroid cancer	5.11e-05	0.00059	CcSEcCtD
Ponatinib—Infestation—Doxorubicin—thyroid cancer	5.11e-05	0.00059	CcSEcCtD
Ponatinib—Neuropathy peripheral—Doxorubicin—thyroid cancer	5.01e-05	0.000579	CcSEcCtD
Ponatinib—Haemoglobin—Epirubicin—thyroid cancer	4.99e-05	0.000576	CcSEcCtD
Ponatinib—Stomatitis—Doxorubicin—thyroid cancer	4.98e-05	0.000575	CcSEcCtD
Ponatinib—Jaundice—Doxorubicin—thyroid cancer	4.98e-05	0.000575	CcSEcCtD
Ponatinib—Urinary tract infection—Doxorubicin—thyroid cancer	4.97e-05	0.000574	CcSEcCtD
Ponatinib—Haemorrhage—Epirubicin—thyroid cancer	4.96e-05	0.000573	CcSEcCtD
Ponatinib—Hypoaesthesia—Epirubicin—thyroid cancer	4.94e-05	0.00057	CcSEcCtD
Ponatinib—Oedema peripheral—Epirubicin—thyroid cancer	4.89e-05	0.000564	CcSEcCtD
Ponatinib—Connective tissue disorder—Epirubicin—thyroid cancer	4.87e-05	0.000563	CcSEcCtD
Ponatinib—Hepatobiliary disease—Doxorubicin—thyroid cancer	4.84e-05	0.000558	CcSEcCtD
Ponatinib—Epistaxis—Doxorubicin—thyroid cancer	4.82e-05	0.000557	CcSEcCtD
Ponatinib—Visual impairment—Epirubicin—thyroid cancer	4.78e-05	0.000552	CcSEcCtD
Ponatinib—Eye disorder—Epirubicin—thyroid cancer	4.64e-05	0.000535	CcSEcCtD
Ponatinib—Haemoglobin—Doxorubicin—thyroid cancer	4.61e-05	0.000533	CcSEcCtD
Ponatinib—Flushing—Epirubicin—thyroid cancer	4.6e-05	0.000531	CcSEcCtD
Ponatinib—Cardiac disorder—Epirubicin—thyroid cancer	4.6e-05	0.000531	CcSEcCtD
Ponatinib—Haemorrhage—Doxorubicin—thyroid cancer	4.59e-05	0.00053	CcSEcCtD
Ponatinib—Hypoaesthesia—Doxorubicin—thyroid cancer	4.57e-05	0.000527	CcSEcCtD
Ponatinib—Oedema peripheral—Doxorubicin—thyroid cancer	4.52e-05	0.000522	CcSEcCtD
Ponatinib—Connective tissue disorder—Doxorubicin—thyroid cancer	4.51e-05	0.000521	CcSEcCtD
Ponatinib—Angiopathy—Epirubicin—thyroid cancer	4.5e-05	0.00052	CcSEcCtD
Ponatinib—Mediastinal disorder—Epirubicin—thyroid cancer	4.47e-05	0.000516	CcSEcCtD
Ponatinib—Chills—Epirubicin—thyroid cancer	4.45e-05	0.000514	CcSEcCtD
Ponatinib—Arrhythmia—Epirubicin—thyroid cancer	4.43e-05	0.000512	CcSEcCtD
Ponatinib—Visual impairment—Doxorubicin—thyroid cancer	4.42e-05	0.000511	CcSEcCtD
Ponatinib—Alopecia—Epirubicin—thyroid cancer	4.38e-05	0.000506	CcSEcCtD
Ponatinib—Mental disorder—Epirubicin—thyroid cancer	4.35e-05	0.000502	CcSEcCtD
Ponatinib—Erythema—Epirubicin—thyroid cancer	4.32e-05	0.000499	CcSEcCtD
Ponatinib—Malnutrition—Epirubicin—thyroid cancer	4.32e-05	0.000499	CcSEcCtD
Ponatinib—Eye disorder—Doxorubicin—thyroid cancer	4.29e-05	0.000495	CcSEcCtD
Ponatinib—Cardiac disorder—Doxorubicin—thyroid cancer	4.26e-05	0.000492	CcSEcCtD
Ponatinib—Flushing—Doxorubicin—thyroid cancer	4.26e-05	0.000492	CcSEcCtD
Ponatinib—Back pain—Epirubicin—thyroid cancer	4.18e-05	0.000482	CcSEcCtD
Ponatinib—Angiopathy—Doxorubicin—thyroid cancer	4.16e-05	0.000481	CcSEcCtD
Ponatinib—Muscle spasms—Epirubicin—thyroid cancer	4.15e-05	0.000479	CcSEcCtD
Ponatinib—Mediastinal disorder—Doxorubicin—thyroid cancer	4.14e-05	0.000478	CcSEcCtD
Ponatinib—Chills—Doxorubicin—thyroid cancer	4.12e-05	0.000475	CcSEcCtD
Ponatinib—Arrhythmia—Doxorubicin—thyroid cancer	4.1e-05	0.000473	CcSEcCtD
Ponatinib—Vision blurred—Epirubicin—thyroid cancer	4.07e-05	0.00047	CcSEcCtD
Ponatinib—Alopecia—Doxorubicin—thyroid cancer	4.06e-05	0.000468	CcSEcCtD
Ponatinib—Mental disorder—Doxorubicin—thyroid cancer	4.02e-05	0.000464	CcSEcCtD
Ponatinib—Erythema—Doxorubicin—thyroid cancer	4e-05	0.000461	CcSEcCtD
Ponatinib—Malnutrition—Doxorubicin—thyroid cancer	4e-05	0.000461	CcSEcCtD
Ponatinib—Anaemia—Epirubicin—thyroid cancer	3.99e-05	0.000461	CcSEcCtD
Ponatinib—Leukopenia—Epirubicin—thyroid cancer	3.87e-05	0.000446	CcSEcCtD
Ponatinib—Back pain—Doxorubicin—thyroid cancer	3.86e-05	0.000446	CcSEcCtD
Ponatinib—Muscle spasms—Doxorubicin—thyroid cancer	3.84e-05	0.000443	CcSEcCtD
Ponatinib—Cough—Epirubicin—thyroid cancer	3.77e-05	0.000435	CcSEcCtD
Ponatinib—Vision blurred—Doxorubicin—thyroid cancer	3.77e-05	0.000435	CcSEcCtD
Ponatinib—Hypertension—Epirubicin—thyroid cancer	3.73e-05	0.00043	CcSEcCtD
Ponatinib—Anaemia—Doxorubicin—thyroid cancer	3.69e-05	0.000426	CcSEcCtD
Ponatinib—Myalgia—Epirubicin—thyroid cancer	3.68e-05	0.000424	CcSEcCtD
Ponatinib—Arthralgia—Epirubicin—thyroid cancer	3.68e-05	0.000424	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	3.65e-05	0.000421	CcSEcCtD
Ponatinib—Dry mouth—Epirubicin—thyroid cancer	3.6e-05	0.000415	CcSEcCtD
Ponatinib—Leukopenia—Doxorubicin—thyroid cancer	3.58e-05	0.000413	CcSEcCtD
Ponatinib—Oedema—Epirubicin—thyroid cancer	3.52e-05	0.000407	CcSEcCtD
Ponatinib—Infection—Epirubicin—thyroid cancer	3.5e-05	0.000404	CcSEcCtD
Ponatinib—Cough—Doxorubicin—thyroid cancer	3.49e-05	0.000402	CcSEcCtD
Ponatinib—Nervous system disorder—Epirubicin—thyroid cancer	3.46e-05	0.000399	CcSEcCtD
Ponatinib—Thrombocytopenia—Epirubicin—thyroid cancer	3.45e-05	0.000398	CcSEcCtD
Ponatinib—Hypertension—Doxorubicin—thyroid cancer	3.45e-05	0.000398	CcSEcCtD
Ponatinib—Skin disorder—Epirubicin—thyroid cancer	3.42e-05	0.000395	CcSEcCtD
Ponatinib—Hyperhidrosis—Epirubicin—thyroid cancer	3.41e-05	0.000393	CcSEcCtD
Ponatinib—Myalgia—Doxorubicin—thyroid cancer	3.4e-05	0.000393	CcSEcCtD
Ponatinib—Arthralgia—Doxorubicin—thyroid cancer	3.4e-05	0.000393	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	3.38e-05	0.00039	CcSEcCtD
Ponatinib—Dry mouth—Doxorubicin—thyroid cancer	3.33e-05	0.000384	CcSEcCtD
Ponatinib—Oedema—Doxorubicin—thyroid cancer	3.26e-05	0.000376	CcSEcCtD
Ponatinib—Infection—Doxorubicin—thyroid cancer	3.24e-05	0.000374	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Epirubicin—thyroid cancer	3.21e-05	0.000371	CcSEcCtD
Ponatinib—Nervous system disorder—Doxorubicin—thyroid cancer	3.2e-05	0.000369	CcSEcCtD
Ponatinib—Thrombocytopenia—Doxorubicin—thyroid cancer	3.19e-05	0.000369	CcSEcCtD
Ponatinib—Insomnia—Epirubicin—thyroid cancer	3.19e-05	0.000368	CcSEcCtD
Ponatinib—Skin disorder—Doxorubicin—thyroid cancer	3.17e-05	0.000366	CcSEcCtD
Ponatinib—Paraesthesia—Epirubicin—thyroid cancer	3.16e-05	0.000365	CcSEcCtD
Ponatinib—Hyperhidrosis—Doxorubicin—thyroid cancer	3.15e-05	0.000364	CcSEcCtD
Ponatinib—Dyspnoea—Epirubicin—thyroid cancer	3.14e-05	0.000363	CcSEcCtD
Ponatinib—Dyspepsia—Epirubicin—thyroid cancer	3.1e-05	0.000358	CcSEcCtD
Ponatinib—Decreased appetite—Epirubicin—thyroid cancer	3.06e-05	0.000354	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Epirubicin—thyroid cancer	3.04e-05	0.000351	CcSEcCtD
Ponatinib—Fatigue—Epirubicin—thyroid cancer	3.04e-05	0.000351	CcSEcCtD
Ponatinib—Pain—Epirubicin—thyroid cancer	3.01e-05	0.000348	CcSEcCtD
Ponatinib—Constipation—Epirubicin—thyroid cancer	3.01e-05	0.000348	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	2.97e-05	0.000343	CcSEcCtD
Ponatinib—Insomnia—Doxorubicin—thyroid cancer	2.95e-05	0.00034	CcSEcCtD
Ponatinib—Paraesthesia—Doxorubicin—thyroid cancer	2.93e-05	0.000338	CcSEcCtD
Ponatinib—Dyspnoea—Doxorubicin—thyroid cancer	2.91e-05	0.000336	CcSEcCtD
Ponatinib—Gastrointestinal pain—Epirubicin—thyroid cancer	2.88e-05	0.000333	CcSEcCtD
Ponatinib—Dyspepsia—Doxorubicin—thyroid cancer	2.87e-05	0.000331	CcSEcCtD
Ponatinib—Decreased appetite—Doxorubicin—thyroid cancer	2.83e-05	0.000327	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Doxorubicin—thyroid cancer	2.82e-05	0.000325	CcSEcCtD
Ponatinib—Fatigue—Doxorubicin—thyroid cancer	2.81e-05	0.000325	CcSEcCtD
Ponatinib—Pain—Doxorubicin—thyroid cancer	2.79e-05	0.000322	CcSEcCtD
Ponatinib—Constipation—Doxorubicin—thyroid cancer	2.79e-05	0.000322	CcSEcCtD
Ponatinib—Body temperature increased—Epirubicin—thyroid cancer	2.79e-05	0.000322	CcSEcCtD
Ponatinib—Abdominal pain—Epirubicin—thyroid cancer	2.79e-05	0.000322	CcSEcCtD
Ponatinib—Gastrointestinal pain—Doxorubicin—thyroid cancer	2.67e-05	0.000308	CcSEcCtD
Ponatinib—Abdominal pain—Doxorubicin—thyroid cancer	2.58e-05	0.000298	CcSEcCtD
Ponatinib—Body temperature increased—Doxorubicin—thyroid cancer	2.58e-05	0.000298	CcSEcCtD
Ponatinib—Asthenia—Epirubicin—thyroid cancer	2.53e-05	0.000292	CcSEcCtD
Ponatinib—Pruritus—Epirubicin—thyroid cancer	2.49e-05	0.000288	CcSEcCtD
Ponatinib—Diarrhoea—Epirubicin—thyroid cancer	2.41e-05	0.000278	CcSEcCtD
Ponatinib—Asthenia—Doxorubicin—thyroid cancer	2.34e-05	0.00027	CcSEcCtD
Ponatinib—Dizziness—Epirubicin—thyroid cancer	2.33e-05	0.000269	CcSEcCtD
Ponatinib—Pruritus—Doxorubicin—thyroid cancer	2.31e-05	0.000266	CcSEcCtD
Ponatinib—Vomiting—Epirubicin—thyroid cancer	2.24e-05	0.000259	CcSEcCtD
Ponatinib—Diarrhoea—Doxorubicin—thyroid cancer	2.23e-05	0.000258	CcSEcCtD
Ponatinib—Rash—Epirubicin—thyroid cancer	2.22e-05	0.000257	CcSEcCtD
Ponatinib—Dermatitis—Epirubicin—thyroid cancer	2.22e-05	0.000256	CcSEcCtD
Ponatinib—Headache—Epirubicin—thyroid cancer	2.21e-05	0.000255	CcSEcCtD
Ponatinib—Dizziness—Doxorubicin—thyroid cancer	2.16e-05	0.000249	CcSEcCtD
Ponatinib—Nausea—Epirubicin—thyroid cancer	2.09e-05	0.000242	CcSEcCtD
Ponatinib—Vomiting—Doxorubicin—thyroid cancer	2.07e-05	0.000239	CcSEcCtD
Ponatinib—Rash—Doxorubicin—thyroid cancer	2.06e-05	0.000237	CcSEcCtD
Ponatinib—Dermatitis—Doxorubicin—thyroid cancer	2.05e-05	0.000237	CcSEcCtD
Ponatinib—Headache—Doxorubicin—thyroid cancer	2.04e-05	0.000236	CcSEcCtD
Ponatinib—Nausea—Doxorubicin—thyroid cancer	1.94e-05	0.000224	CcSEcCtD
Ponatinib—SRC—Disease—TERT—thyroid cancer	3.35e-06	4.28e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—KRAS—thyroid cancer	3.35e-06	4.28e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—PTGS2—thyroid cancer	3.35e-06	4.28e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PRKAR1A—thyroid cancer	3.35e-06	4.28e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—PTEN—thyroid cancer	3.34e-06	4.27e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—PTEN—thyroid cancer	3.34e-06	4.27e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—KRAS—thyroid cancer	3.32e-06	4.25e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—CCND1—thyroid cancer	3.32e-06	4.24e-05	CbGpPWpGaD
Ponatinib—KIT—Innate Immune System—AKT1—thyroid cancer	3.31e-06	4.23e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CDK1—thyroid cancer	3.26e-06	4.16e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TERT—thyroid cancer	3.24e-06	4.13e-05	CbGpPWpGaD
Ponatinib—FGFR2—Adaptive Immune System—AKT1—thyroid cancer	3.23e-06	4.13e-05	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—HRAS—thyroid cancer	3.23e-06	4.13e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—HIF1A—thyroid cancer	3.21e-06	4.1e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—TPR—thyroid cancer	3.21e-06	4.1e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—PTEN—thyroid cancer	3.2e-06	4.09e-05	CbGpPWpGaD
Ponatinib—KIT—Adaptive Immune System—AKT1—thyroid cancer	3.18e-06	4.06e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—PTEN—thyroid cancer	3.17e-06	4.06e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—PTEN—thyroid cancer	3.17e-06	4.04e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PRKAR1A—thyroid cancer	3.15e-06	4.03e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—PTEN—thyroid cancer	3.14e-06	4.02e-05	CbGpPWpGaD
Ponatinib—FGFR1—Innate Immune System—AKT1—thyroid cancer	3.14e-06	4.01e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Innate Immune System—AKT1—thyroid cancer	3.13e-06	4e-05	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—HRAS—thyroid cancer	3.13e-06	4e-05	CbGpPWpGaD
Ponatinib—LYN—Developmental Biology—AKT1—thyroid cancer	3.13e-06	4e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—BRAF—thyroid cancer	3.12e-06	3.99e-05	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—HRAS—thyroid cancer	3.11e-06	3.98e-05	CbGpPWpGaD
Ponatinib—ABL1—Developmental Biology—AKT1—thyroid cancer	3.11e-06	3.98e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—NRAS—thyroid cancer	3.1e-06	3.97e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HIF1A—thyroid cancer	3.09e-06	3.95e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—PTEN—thyroid cancer	3.09e-06	3.95e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—BRAF—thyroid cancer	3.07e-06	3.92e-05	CbGpPWpGaD
Ponatinib—LYN—Hemostasis—AKT1—thyroid cancer	3.07e-06	3.92e-05	CbGpPWpGaD
Ponatinib—ABL1—Hemostasis—AKT1—thyroid cancer	3.05e-06	3.9e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—NRAS—thyroid cancer	3.04e-06	3.88e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—KRAS—thyroid cancer	3.02e-06	3.86e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—KRAS—thyroid cancer	3.02e-06	3.86e-05	CbGpPWpGaD
Ponatinib—FGFR1—Adaptive Immune System—AKT1—thyroid cancer	3.02e-06	3.85e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Adaptive Immune System—AKT1—thyroid cancer	3.01e-06	3.84e-05	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—HRAS—thyroid cancer	3e-06	3.84e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—BRAF—thyroid cancer	3e-06	3.83e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—NRAS—thyroid cancer	2.98e-06	3.81e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—HRAS—thyroid cancer	2.98e-06	3.81e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—NRAS—thyroid cancer	2.98e-06	3.81e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—TP53—thyroid cancer	2.98e-06	3.81e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PTGS2—thyroid cancer	2.97e-06	3.8e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—KRAS—thyroid cancer	2.97e-06	3.79e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NRG1—thyroid cancer	2.95e-06	3.77e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TP53—thyroid cancer	2.95e-06	3.77e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—PTEN—thyroid cancer	2.93e-06	3.74e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—SLC5A5—thyroid cancer	2.92e-06	3.74e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—PTEN—thyroid cancer	2.92e-06	3.73e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—BRAF—thyroid cancer	2.91e-06	3.72e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—BRAF—thyroid cancer	2.9e-06	3.71e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—KRAS—thyroid cancer	2.9e-06	3.7e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—CCND1—thyroid cancer	2.89e-06	3.69e-05	CbGpPWpGaD
Ponatinib—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	2.87e-06	3.67e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—NRAS—thyroid cancer	2.86e-06	3.65e-05	CbGpPWpGaD
Ponatinib—FGFR3—Immune System—AKT1—thyroid cancer	2.85e-06	3.65e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—HRAS—thyroid cancer	2.85e-06	3.64e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—RXRA—thyroid cancer	2.84e-06	3.62e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—NRAS—thyroid cancer	2.83e-06	3.62e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—HRAS—thyroid cancer	2.82e-06	3.61e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—NRAS—thyroid cancer	2.82e-06	3.61e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—NRAS—thyroid cancer	2.8e-06	3.58e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—PTEN—thyroid cancer	2.79e-06	3.57e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—PTEN—thyroid cancer	2.79e-06	3.56e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—PTEN—thyroid cancer	2.78e-06	3.55e-05	CbGpPWpGaD
Ponatinib—LYN—Innate Immune System—AKT1—thyroid cancer	2.76e-06	3.53e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—NRAS—thyroid cancer	2.75e-06	3.52e-05	CbGpPWpGaD
Ponatinib—ABL1—Innate Immune System—AKT1—thyroid cancer	2.75e-06	3.51e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.74e-06	3.5e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—KRAS—thyroid cancer	2.67e-06	3.41e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—BRAF—thyroid cancer	2.66e-06	3.39e-05	CbGpPWpGaD
Ponatinib—LYN—Adaptive Immune System—AKT1—thyroid cancer	2.65e-06	3.39e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TERT—thyroid cancer	2.65e-06	3.39e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—TP53—thyroid cancer	2.64e-06	3.37e-05	CbGpPWpGaD
Ponatinib—FGFR3—Disease—AKT1—thyroid cancer	2.63e-06	3.37e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NRG1—thyroid cancer	2.61e-06	3.34e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—KRAS—thyroid cancer	2.61e-06	3.34e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—NRAS—thyroid cancer	2.61e-06	3.34e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—NRAS—thyroid cancer	2.61e-06	3.33e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PTEN—thyroid cancer	2.59e-06	3.31e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—HRAS—thyroid cancer	2.57e-06	3.28e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—KRAS—thyroid cancer	2.57e-06	3.28e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—KRAS—thyroid cancer	2.56e-06	3.28e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—HRAS—thyroid cancer	2.56e-06	3.28e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—BRAF—thyroid cancer	2.56e-06	3.27e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—SLC5A5—thyroid cancer	2.55e-06	3.25e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HIF1A—thyroid cancer	2.54e-06	3.24e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—HRAS—thyroid cancer	2.52e-06	3.22e-05	CbGpPWpGaD
Ponatinib—LCK—Hemostasis—AKT1—thyroid cancer	2.51e-06	3.21e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PPARG—thyroid cancer	2.5e-06	3.19e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—AKT1—thyroid cancer	2.49e-06	3.19e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—NRAS—thyroid cancer	2.49e-06	3.18e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—NRAS—thyroid cancer	2.49e-06	3.18e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—NRAS—thyroid cancer	2.48e-06	3.17e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—HRAS—thyroid cancer	2.46e-06	3.15e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—KRAS—thyroid cancer	2.46e-06	3.14e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—RXRA—thyroid cancer	2.46e-06	3.14e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—KRAS—thyroid cancer	2.44e-06	3.11e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—KRAS—thyroid cancer	2.43e-06	3.11e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—PTGS2—thyroid cancer	2.42e-06	3.1e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—KRAS—thyroid cancer	2.41e-06	3.08e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—SLC5A5—thyroid cancer	2.4e-06	3.07e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.39e-06	3.05e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—KRAS—thyroid cancer	2.37e-06	3.03e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TERT—thyroid cancer	2.35e-06	3e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—PTEN—thyroid cancer	2.29e-06	2.92e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CCND1—thyroid cancer	2.28e-06	2.91e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—HRAS—thyroid cancer	2.27e-06	2.9e-05	CbGpPWpGaD
Ponatinib—SRC—Developmental Biology—AKT1—thyroid cancer	2.27e-06	2.9e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—AKT1—thyroid cancer	2.26e-06	2.89e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—KRAS—thyroid cancer	2.25e-06	2.88e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HIF1A—thyroid cancer	2.25e-06	2.87e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—KRAS—thyroid cancer	2.24e-06	2.87e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CCND1—thyroid cancer	2.24e-06	2.86e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—AKT1—thyroid cancer	2.23e-06	2.85e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—HRAS—thyroid cancer	2.22e-06	2.84e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PTEN—thyroid cancer	2.2e-06	2.81e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TP53—thyroid cancer	2.18e-06	2.79e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—HRAS—thyroid cancer	2.18e-06	2.79e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—HRAS—thyroid cancer	2.18e-06	2.79e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—AKT1—thyroid cancer	2.17e-06	2.78e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PTEN—thyroid cancer	2.16e-06	2.76e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PTGS2—thyroid cancer	2.14e-06	2.74e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—KRAS—thyroid cancer	2.14e-06	2.74e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—KRAS—thyroid cancer	2.14e-06	2.74e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—RXRA—thyroid cancer	2.14e-06	2.73e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—KRAS—thyroid cancer	2.13e-06	2.73e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CCND1—thyroid cancer	2.13e-06	2.72e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CCND1—thyroid cancer	2.12e-06	2.71e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—PTEN—thyroid cancer	2.11e-06	2.7e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—BRAF—thyroid cancer	2.1e-06	2.68e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TPR—thyroid cancer	2.1e-06	2.68e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—HRAS—thyroid cancer	2.09e-06	2.67e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—HRAS—thyroid cancer	2.07e-06	2.65e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—HRAS—thyroid cancer	2.07e-06	2.64e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	2.06e-06	2.63e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PTEN—thyroid cancer	2.05e-06	2.62e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—HRAS—thyroid cancer	2.05e-06	2.62e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PTEN—thyroid cancer	2.05e-06	2.62e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—NRAS—thyroid cancer	2.04e-06	2.61e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—PTEN—thyroid cancer	2.03e-06	2.59e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—RXRA—thyroid cancer	2.02e-06	2.58e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—HRAS—thyroid cancer	2.01e-06	2.58e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—AKT1—thyroid cancer	2e-06	2.56e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTGS2—thyroid cancer	1.97e-06	2.51e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—NRAS—thyroid cancer	1.96e-06	2.51e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—AKT1—thyroid cancer	1.96e-06	2.51e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—NRAS—thyroid cancer	1.93e-06	2.46e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—AKT1—thyroid cancer	1.93e-06	2.46e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—AKT1—thyroid cancer	1.92e-06	2.46e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—HRAS—thyroid cancer	1.91e-06	2.44e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—HRAS—thyroid cancer	1.91e-06	2.44e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—thyroid cancer	1.9e-06	2.43e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—NRAS—thyroid cancer	1.88e-06	2.41e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PTEN—thyroid cancer	1.87e-06	2.39e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCND1—thyroid cancer	1.87e-06	2.39e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—BRAF—thyroid cancer	1.86e-06	2.38e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—AKT1—thyroid cancer	1.84e-06	2.36e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NRAS—thyroid cancer	1.83e-06	2.34e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—AKT1—thyroid cancer	1.83e-06	2.34e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NRAS—thyroid cancer	1.83e-06	2.33e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—AKT1—thyroid cancer	1.82e-06	2.33e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—HRAS—thyroid cancer	1.82e-06	2.33e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—HRAS—thyroid cancer	1.82e-06	2.33e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—HRAS—thyroid cancer	1.81e-06	2.32e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—AKT1—thyroid cancer	1.81e-06	2.32e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—NRAS—thyroid cancer	1.81e-06	2.31e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PTEN—thyroid cancer	1.8e-06	2.31e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PPARG—thyroid cancer	1.79e-06	2.29e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—AKT1—thyroid cancer	1.78e-06	2.27e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—KRAS—thyroid cancer	1.76e-06	2.25e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTEN—thyroid cancer	1.71e-06	2.19e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—KRAS—thyroid cancer	1.69e-06	2.16e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—AKT1—thyroid cancer	1.69e-06	2.16e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—AKT1—thyroid cancer	1.68e-06	2.15e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—NRAS—thyroid cancer	1.67e-06	2.13e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—KRAS—thyroid cancer	1.66e-06	2.12e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—KRAS—thyroid cancer	1.62e-06	2.07e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NRAS—thyroid cancer	1.61e-06	2.06e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—AKT1—thyroid cancer	1.61e-06	2.06e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—AKT1—thyroid cancer	1.61e-06	2.05e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—AKT1—thyroid cancer	1.6e-06	2.05e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—KRAS—thyroid cancer	1.58e-06	2.01e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—KRAS—thyroid cancer	1.57e-06	2.01e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—SLC5A5—thyroid cancer	1.57e-06	2e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—KRAS—thyroid cancer	1.56e-06	1.99e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PPARG—thyroid cancer	1.55e-06	1.98e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCND1—thyroid cancer	1.53e-06	1.96e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—thyroid cancer	1.5e-06	1.92e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—AKT1—thyroid cancer	1.49e-06	1.91e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—HRAS—thyroid cancer	1.49e-06	1.91e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PTEN—thyroid cancer	1.48e-06	1.89e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—thyroid cancer	1.48e-06	1.89e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—HRAS—thyroid cancer	1.44e-06	1.84e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—KRAS—thyroid cancer	1.44e-06	1.84e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—HRAS—thyroid cancer	1.41e-06	1.8e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTGS2—thyroid cancer	1.41e-06	1.8e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—thyroid cancer	1.4e-06	1.79e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—thyroid cancer	1.4e-06	1.78e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KRAS—thyroid cancer	1.39e-06	1.77e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—HRAS—thyroid cancer	1.38e-06	1.76e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCND1—thyroid cancer	1.36e-06	1.73e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PPARG—thyroid cancer	1.35e-06	1.73e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—HRAS—thyroid cancer	1.34e-06	1.71e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—HRAS—thyroid cancer	1.34e-06	1.71e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—HRAS—thyroid cancer	1.32e-06	1.69e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NRAS—thyroid cancer	1.32e-06	1.69e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—AKT1—thyroid cancer	1.32e-06	1.69e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—RXRA—thyroid cancer	1.32e-06	1.68e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PTEN—thyroid cancer	1.31e-06	1.67e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PPARG—thyroid cancer	1.27e-06	1.63e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—AKT1—thyroid cancer	1.27e-06	1.62e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—AKT1—thyroid cancer	1.25e-06	1.59e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—thyroid cancer	1.23e-06	1.57e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTEN—thyroid cancer	1.23e-06	1.57e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—HRAS—thyroid cancer	1.22e-06	1.56e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTGS2—thyroid cancer	1.22e-06	1.56e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—AKT1—thyroid cancer	1.22e-06	1.56e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—AKT1—thyroid cancer	1.18e-06	1.51e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—AKT1—thyroid cancer	1.18e-06	1.51e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—HRAS—thyroid cancer	1.18e-06	1.51e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NRAS—thyroid cancer	1.17e-06	1.49e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—AKT1—thyroid cancer	1.17e-06	1.49e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KRAS—thyroid cancer	1.14e-06	1.45e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—AKT1—thyroid cancer	1.08e-06	1.38e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTEN—thyroid cancer	1.06e-06	1.36e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS2—thyroid cancer	1.06e-06	1.36e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—AKT1—thyroid cancer	1.04e-06	1.33e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—thyroid cancer	1.01e-06	1.29e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KRAS—thyroid cancer	1.01e-06	1.29e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS2—thyroid cancer	1e-06	1.28e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—AKT1—thyroid cancer	9.88e-07	1.26e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HRAS—thyroid cancer	9.66e-07	1.23e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTEN—thyroid cancer	9.27e-07	1.18e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—thyroid cancer	8.94e-07	1.14e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTEN—thyroid cancer	8.73e-07	1.12e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HRAS—thyroid cancer	8.55e-07	1.09e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—AKT1—thyroid cancer	8.53e-07	1.09e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PPARG—thyroid cancer	8.32e-07	1.06e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—AKT1—thyroid cancer	7.55e-07	9.65e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—AKT1—thyroid cancer	7.08e-07	9.05e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS2—thyroid cancer	6.55e-07	8.37e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—AKT1—thyroid cancer	6.13e-07	7.83e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTEN—thyroid cancer	5.71e-07	7.3e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—AKT1—thyroid cancer	5.34e-07	6.83e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—AKT1—thyroid cancer	5.03e-07	6.43e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—AKT1—thyroid cancer	3.29e-07	4.21e-06	CbGpPWpGaD
